About Raptor Pharmaceutical (NASDAQ:RPTP)
Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-77.01%
Return on Assets-15.64%
Raptor Pharmaceutical (NASDAQ:RPTP) Frequently Asked Questions
What is Raptor Pharmaceutical's stock symbol?
Raptor Pharmaceutical trades on the NASDAQ under the ticker symbol "RPTP."
How were Raptor Pharmaceutical's earnings last quarter?
Raptor Pharmaceutical Corp (NASDAQ:RPTP) released its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.02. The biotechnology company earned $32.05 million during the quarter, compared to analysts' expectations of $28.52 million. Raptor Pharmaceutical had a negative return on equity of 77.01% and a negative net margin of 43.75%. The company's quarterly revenue was up 37.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.17) earnings per share. View Raptor Pharmaceutical's Earnings History.
Has Raptor Pharmaceutical been receiving favorable news coverage?
Headlines about RPTP stock have been trending somewhat positive on Monday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Raptor Pharmaceutical earned a news impact score of 0.01 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 44.86 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Raptor Pharmaceutical?
Shares of RPTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Raptor Pharmaceutical's stock price today?
One share of RPTP stock can currently be purchased for approximately $9.00.
How big of a company is Raptor Pharmaceutical?
Raptor Pharmaceutical has a market capitalization of $767.76 million. Raptor Pharmaceutical employs 158 workers across the globe.
How can I contact Raptor Pharmaceutical?
Raptor Pharmaceutical's mailing address is 7 Hamilton Lndg Ste 100, NOVATO, CA 94949-8283, United States. The biotechnology company can be reached via phone at +1-415-4086200.
MarketBeat Community Rating for Raptor Pharmaceutical (RPTP)MarketBeat's community ratings are surveys of what our community members think about Raptor Pharmaceutical and other stocks. Vote "Outperform" if you believe RPTP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPTP will underperform the S&P 500 over the long term. You may vote once every thirty days.